SYNGENE INTERNATIONAL LIMITED UNIT XI

SYNGENE INTERNATIONAL LIMITED UNIT XI COMPANY PROFILE

Syngene International Limited Unit XI is a manufacturing and research and development facility. It is not a trading company.

COMPANY OVERVIEW

Syngene International Limited Unit XI is an operational unit of Syngene International Limited, a leading integrated research, development, and manufacturing organization (CRDMO) based in India. Syngene provides comprehensive discovery, development, and manufacturing services to pharmaceutical, biotechnology, nutrition, animal health, and specialty chemical companies worldwide.

The Unit XI facility is an integral part of Syngene's extensive infrastructure, contributing to its capabilities in various stages of the drug discovery and development process, as well as manufacturing. These services typically include:

Discovery Services: Target identification, validation, lead generation, and optimization.

Development Services: Preclinical and clinical development, including toxicology, pharmacokinetics, and clinical trial support.

Manufacturing Services: Production of active pharmaceutical ingredients (APIs), intermediates, and drug products for clinical trials and commercial supply. This includes both small molecules and biologics.

Analytical Services: Comprehensive analytical testing and quality control.

As a CRDMO, Syngene International Limited, including its Unit XI, plays a crucial role in enabling its clients to bring new products to market faster and more efficiently by leveraging its scientific expertise, state-of-the-art facilities, and regulatory compliance. The company operates under stringent quality standards and regulatory guidelines to ensure the safety and efficacy of the products and services it delivers.

Syngene International Limited Unit XI, as a part of Syngene International, operates as a Contract Research, Development, and Manufacturing Organization (CRDMO). Therefore, it does not typically produce or sell its own branded end-products directly to the market. Instead, its "products" are the comprehensive scientific research, development, and manufacturing services it provides to global pharmaceutical, biotechnology, nutrition, animal health, and specialty chemical companies.

These services include:

Discovery Services

Medicinal Chemistry

Synthetic Chemistry

In Vitro Biology and Screening

In Vivo Pharmacology

Structural Biology

Data Sciences

Development Services

Process Chemistry and Scale-up

Analytical Development and Validation

Formulation Development

Preclinical and Clinical Development Support

Manufacturing Services (CDMO)

Active Pharmaceutical Ingredient (API) Manufacturing

Drug Product Manufacturing (e.g., oral solid dosages, sterile injectables)

Biologics Manufacturing (e.g., monoclonal antibodies, recombinant proteins)

Oligonucleotide Synthesis

Peptide Synthesis

Clinical Trial Material (CTM) Manufacturing

Commercial Manufacturing

Essentially, Syngene International Limited Unit XI produces molecules, compounds, and drug products on behalf of its clients, who then market these final products under their respective brands. Syngene itself does not own the intellectual property of these final products or sell them under its own name.